Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe.
To read more about Alpharadin go to:
“On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life” at: http://advancedprostatecancer.net/?p=2823 and to:
“Alpharadin Extends Life in Men with Advanced Prostate Cancer” at: http://advancedprostatecancer.net/?p=2814
Until it is actually approved, Alpharadin is unavailable to men who would benefit from it. However, Bayer is starting an expanded access, or compassionate use trial of Alpharadin for men with metastatic, castration-resistant prostate cancer. Participation in this trial will allow eligible men to get early access to the drug at no cost.
To learn more about this trial go to: http://clinicaltrials.gov/ct2/show/NCT01516762
Currently, there isn’t any contact information being published. However, if you are interested in participating in the trial or wish to learn more about the trial you should send an email to:
In your email indicate that you are interested in the Alpharadin Compassionate Use Trial. Indicate that you wish to confirm your eligibility for this study. Give them your home address, including your city and state of residence. Include your email address as well as your telephone number.
Joel T. Nowak, M.A., M.S.W.